All In Biotech

Drug Trial Radar · NCT01924325

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design

Last checked: Nov 19, 2026Latest source record: Aug 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

10,000

Planned (sponsor's estimate)

Start

Jan 2014

Primary completion

Dec 2015

Study completion Jul 2016

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 16, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin treatment reduced the risk of recurrent stroke and was not associated with increased hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants with less risk of bleeding events. To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized, double-blind, multicenter, controlled clinical trial has been designed. The investigators will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling cerebrovascular event.

Conditions

  • Ischemic Stroke
  • TIA

Interventions

  • ApixabanDrug

    orally active direct factor Xa inhibitor

  • ClopidogrelDrug

    an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor

  • AspirinDrug

    a non-steroidal anti-inflammatory drug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. percentage of patients with new stroke (ischemic or hemorrhage)Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital

    Xi'an, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.